<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(4)</volume><submitter>Leung HKM</submitter><pubmed_abstract>Colorectal cancer (CRC) is one of the most common cancers worldwide. The standard CRC chemo drug, 5-Fluorouracil (5-FU), has a poor response rate and chemoresistance, prompting the need for a more effective and affordable treatment. In this study, we aimed to evaluate whether Prohep, a novel probiotic mixture, would alleviate azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colorectal tumorigenesis and enhance 5-FU efficacy and its mechanism. Our results suggested that Prohep showed stronger anti-tumorigenesis effects than 5-FU alone or when combined in the AOM/DSS model. Prohep significantly reduced the total tumor count, total tumor size, caecum weight, colonic crypt depth, colonic inflammation, and collagen fibrosis. Prohep downregulated pro-inflammatory TNF-α and proliferative p-S</pubmed_abstract><journal>Probiotics and antimicrobial proteins</journal><pagination>2227-2243</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12405048</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Probiotic Mixture Attenuates Colorectal Tumorigenesis in Murine AOM/DSS Model by Suppressing STAT3, Inducing Apoptotic p53 and Modulating Gut Microbiota.</pubmed_title><pmcid>PMC12405048</pmcid><pubmed_authors>Zhang F</pubmed_authors><pubmed_authors>Lo EKK</pubmed_authors><pubmed_authors>Ismaiah MJ</pubmed_authors><pubmed_authors>Felicianna</pubmed_authors><pubmed_authors>El-Nezami H</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Leung HKM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Probiotic Mixture Attenuates Colorectal Tumorigenesis in Murine AOM/DSS Model by Suppressing STAT3, Inducing Apoptotic p53 and Modulating Gut Microbiota.</name><description>Colorectal cancer (CRC) is one of the most common cancers worldwide. The standard CRC chemo drug, 5-Fluorouracil (5-FU), has a poor response rate and chemoresistance, prompting the need for a more effective and affordable treatment. In this study, we aimed to evaluate whether Prohep, a novel probiotic mixture, would alleviate azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colorectal tumorigenesis and enhance 5-FU efficacy and its mechanism. Our results suggested that Prohep showed stronger anti-tumorigenesis effects than 5-FU alone or when combined in the AOM/DSS model. Prohep significantly reduced the total tumor count, total tumor size, caecum weight, colonic crypt depth, colonic inflammation, and collagen fibrosis. Prohep downregulated pro-inflammatory TNF-α and proliferative p-S</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-05-29T21:18:04.253Z</modification><creation>2026-04-08T05:59:02.614Z</creation></dates><accession>S-EPMC12405048</accession><cross_references><pubmed>39641861</pubmed><doi>10.1007/s12602-024-10405-1</doi></cross_references></HashMap>